The Effect of a Vibratory Lumber Orthosis on Walking Velocity in Patients with Parkinson's Disease

2009 ◽  
Vol 33 (1) ◽  
pp. 82-88 ◽  
Author(s):  
Kamiar Ghoseiri ◽  
Bijan Forogh ◽  
Mohammad Ali Sanjari ◽  
Ahlam Bavi
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurological Diseases ◽  
The Body ◽  
Lumbar Region ◽  
Vibratory Stimulus ◽  
Vibratory Stimulation ◽  
Gait Stability ◽  
Walking Velocity ◽  
Design And Testing

This paper explores the use of biofeedback to improve gait in Parkinson's disease (PD) and, in particular, reports on the design and testing of a new vibratory orthosis. The orthosis causes a rhythmic vibratory stimulus to be applied to one or other side of the lumbar region. The stimulus is synchronized with stepping through the use of heel-located switches; each switch controls the stimulus to the corresponding side of the body. In the experimental evaluation it was hypothesized that step-synchronized, vibratory stimulation applied to the lumbar region will lead to an increase in walking velocity in patients with idiopathic Parkinson's disease. Subjects were asked to carry out walking trials under two conditions. In one condition, the vibratory orthosis was active; in the other condition the vibratory orthosis was inactive. Walking velocity was measured over a straight, 10 m walkway. A comparison between the two conditions using a paired t-test showed a significant increase in walking velocity when the vibratory orthosis was active, compared with the inactive condition. It was speculated that use of the vibratory orthosis, which stimulates proprioceptive receptors, may lead to an improvement in gait, stability and may support gait re-education in PD patients. It was also suggested that the results may inform future ideas for rehabilitation of similar neurological diseases.

Therapeutic Effects of Ketogenic Diet Components on Parkinson's Disease

2020 ◽  
pp. 56-63
Author(s):  
OJS Admin
Keyword(s):  
Parkinson’S Disease ◽  
Fatty Acids ◽  
Parkinson's Disease ◽  
Ketogenic Diet ◽  
Neurological Diseases ◽  
The Body ◽  
Therapeutic Effects ◽  
Omega 3 ◽  
Neuroprotective Effects ◽  
Omega 6

Parkinson's disease is a neurodegenerative disease and no proper treatment or cure has been developed for it till now. Worldwide the incidence of disease has been increased with age. Latest researches have focused on the dietary aspects of Parkinson's and have revealed that a ketogenic diet may be benecial in prevention and for therapy. The main aim of this review article was to explore the dietary elements present in ketogenic diet and their respective roles in the body with link to Parkinson's disease. Ketogenic diet has been used in many neurological diseases due to its neuroprotective effects. Ketogenic diet is a normal caloric diet that composed of with high fat (mostly composed with polyunsaturated fatty acids), medium protein and low in carbohydrates. The composition of this diet makes body to utilize fatand ketones for energy by altering glucose. The major constituents present in a ketogenic diet which have neuroprotective effects against Parkinson's are; B complex vitamins, Omega-3 Fatty Acids, Omega-6 Fatty acids and Vitamin D. The benecial effects have been evaluated regarding the role of constituents present in a ketogenic diet on Parkinson's disease. The need for further researches, especially clinical trials forthe different constituents of ketogenic diet and their neuroprotective properties are still required.

scholarly journals An Integrated Multi-Sensor Approach for the Remote Monitoring of Parkinson’s Disease

Sensors ◽  
2019 ◽  
Vol 19 (21) ◽  
pp. 4764 ◽  
Author(s):  
Giovanni Albani ◽  
Claudia Ferraris ◽  
Roberto Nerino ◽  
Antonio Chimienti ◽  
Giuseppe Pettiti ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Remote Monitoring ◽  
Rating Scale ◽  
Population Aging ◽  
Neurological Diseases ◽  
Low Cost ◽  
Wearable Sensors ◽  
Cost Effective ◽  
The Body

The increment of the prevalence of neurological diseases due to the trend in population aging demands for new strategies in disease management. In Parkinson’s disease (PD), these strategies should aim at improving diagnosis accuracy and frequency of the clinical follow-up by means of decentralized cost-effective solutions. In this context, a system suitable for the remote monitoring of PD subjects is presented. It consists of the integration of two approaches investigated in our previous works, each one appropriate for the movement analysis of specific parts of the body: low-cost optical devices for the upper limbs and wearable sensors for the lower ones. The system performs the automated assessments of six motor tasks of the unified Parkinson’s disease rating scale, and it is equipped with a gesture-based human machine interface designed to facilitate the user interaction and the system management. The usability of the system has been evaluated by means of standard questionnaires, and the accuracy of the automated assessment has been verified experimentally. The results demonstrate that the proposed solution represents a substantial improvement in PD assessment respect to the former two approaches treated separately, and a new example of an accurate, feasible and cost-effective mean for the decentralized management of PD.

The Use of Vibrotactile Stimulation for Improving Manual Tasks in Parkinson's Disease Patients

2016 ◽  
Vol 879 ◽  
pp. 2348-2351
Author(s):  
Sandro Gentili ◽  
Maria Richetta ◽  
Stefano Mugnaini ◽  
S. Mancini ◽  
Enrico M. Staderini
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nervous System ◽  
Evoked Potentials ◽  
The Body ◽  
Leap Motion ◽  
Vibratory Stimulation ◽  
Vibrotactile Stimulation ◽  
Experimental Apparatus ◽  
Manual Tasks

In spite of the potentially harmful effects of vibrations on the human body, a new path was recently opened for the use of these mechanical means in the therapeutic field. The stimulation of proprioceptive and exteroceptive sensitivity is the main target in both peripheral (diabetes type 1 and type 2) and central (stroke, Parkinson's disease multiple sclerosis) nervous system disorders, particularly for the recovery and maintenance of functional state. By the way the response to the treatment is highly variable from subject to subject. Our experimental apparatus consists of a virtual reality system "LEAP Motion" which involves the patient in the execution of visuo-manual tasks in a virtual environment while receiving vibrotactile stimulation. We also used a modular 36 channels EEG system and a vibratory stimulation system able of delivering vibratory stimuli perpendicular and tangential to the body surface area.The study evaluation of motor performance and the ability to perform the tasks of visuomotor task assigned, in the presence and absence of vibratory stimulation and in real time, evoked potentials in the cortex.The vibration frequency extended from 5 to 200 Hz and with accelerations between 0.3G and 1,5G with displacement amplitude of about 0.5 mm applied on the affected limb hand. As the frequency, the amplitude and the direction of the vibration may vary we studied the relationship between the characteristics of the stimulus and the perception in the cerebral cortex, or other levels of the nervous system, studying potential models of elicitation of the somatosensory system. In this regard, our study took into account patients with Parkinson's disease and in particular evoked potentials N18 N20 N24 N30 particularly related to tactile stimulus, and indicative of the level of perception and processing in the brain of the Parkinson's patient.

SPECT-Befunde bei Hemiparkinson-Syndrom mit 99mTc-HMPAO

1989 ◽  
Vol 28 (03) ◽  
pp. 92-94 ◽  
Author(s):  
C. Neumann ◽  
H. Baas ◽  
R. Hefner ◽  
G. Hör
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Basal Ganglia ◽  
Neuronal Activity ◽  
Tracer Uptake ◽  
The Body ◽  
99Mtc Hmpao ◽  
Do So

The symptoms of Parkinson’s disease often begin on one side of the body and continue to do so as the disease progresses. First SPECT results in 4 patients with hemiparkinsonism using 99mTc-HMPAO as perfusion marker are reported. Three patients exhibited reduced tracer uptake in the contralateral basal ganglia One patient who was under therapy for 1 year, showed a different perfusion pattern with reduced uptake in both basal ganglia. These results might indicate reduced perfusion secondary to reduced striatal neuronal activity.

Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes

2021 ◽  
pp. 1-11
Author(s):  
Karoline Knudsen ◽  
Tatyana D. Fedorova ◽  
Jacob Horsager ◽  
Katrine B. Andersen ◽  
Casper Skjærbæk ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
De Novo ◽  
Specific Binding ◽  
Asymmetry Index ◽  
The Body ◽  
Specific Binding Ratio ◽  
Dat Spect ◽  
Vagal Innervation ◽  
Nigrostriatal Degeneration

Background: We have hypothesized that Parkinson’s disease (PD) comprises two subtypes. Brain-first, where pathogenic α-synuclein initially forms unilaterally in one hemisphere leading to asymmetric nigrostriatal degeneration, and body-first with initial enteric pathology, which spreads through overlapping vagal innervation leading to more symmetric brainstem involvement and hence more symmetric nigrostriatal degeneration. Isolated REM sleep behaviour disorder has been identified as a strong marker of the body-first type. Objective: To analyse striatal asymmetry in [18F]FDOPA PET and [123I]FP-CIT DaT SPECT data from iRBD patients, de novo PD patients with RBD (PD +RBD) and de novo PD patients without RBD (PD - RBD). These groups were defined as prodromal body-first, de novo body-first, and de novo brain-first, respectively. Methods: We included [18F]FDOPA PET scans from 21 iRBD patients, 11 de novo PD +RBD, 22 de novo PD - RBD, and 18 controls subjects. Also, [123I]FP-CIT DaT SPECT data from iRBD and de novo PD patients with unknown RBD status from the PPPMI dataset was analysed. Lowest putamen specific binding ratio and putamen asymmetry index (AI) was defined. Results: Nigrostriatal degeneration was significantly more symmetric in patients with RBD versus patients without RBD or with unknown RBD status in both FDOPA (p = 0.001) and DaT SPECT (p = 0.001) datasets. Conclusion: iRBD subjects and de novo PD +RBD patients present with significantly more symmetric nigrostriatal dopaminergic degeneration compared to de novo PD - RBD patients. The results support the hypothesis that body-first PD is characterized by more symmetric distribution most likely due to more symmetric propagation of pathogenic α-synuclein compared to brain-first PD.

scholarly journals Validation of IMU-based gait event detection during curved walking and turning in older adults and Parkinson’s Disease patients

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Robbin Romijnders ◽  
Elke Warmerdam ◽  
Clint Hansen ◽  
Julius Welzel ◽  
Gerhard Schmidt ◽  
...  
Keyword(s):  
Older Adults ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Daily Life ◽  
Neurological Diseases ◽  
Detection Performance ◽  
Measurement Unit ◽  
Straight Line ◽  
Optical Motion ◽  
Task Conditions

Abstract Background Identification of individual gait events is essential for clinical gait analysis, because it can be used for diagnostic purposes or tracking disease progression in neurological diseases such as Parkinson’s disease. Previous research has shown that gait events can be detected from a shank-mounted inertial measurement unit (IMU), however detection performance was often evaluated only from straight-line walking. For use in daily life, the detection performance needs to be evaluated in curved walking and turning as well as in single-task and dual-task conditions. Methods Participants (older adults, people with Parkinson’s disease, or people who had suffered from a stroke) performed three different walking trials: (1) straight-line walking, (2) slalom walking, (3) Stroop-and-walk trial. An optical motion capture system was used a reference system. Markers were attached to the heel and toe regions of the shoe, and participants wore IMUs on the lateral sides of both shanks. The angular velocity of the shank IMUs was used to detect instances of initial foot contact (IC) and final foot contact (FC), which were compared to reference values obtained from the marker trajectories. Results The detection method showed high recall, precision and F1 scores in different populations for both initial contacts and final contacts during straight-line walking (IC: recall $$=$$ = 100%, precision $$=$$ = 100%, F1 score $$=$$ = 100%; FC: recall $$=$$ = 100%, precision $$=$$ = 100%, F1 score $$=$$ = 100%), slalom walking (IC: recall $$=$$ = 100%, precision $$\ge$$ ≥ 99%, F1 score $$=$$ = 100%; FC: recall $$=$$ = 100%, precision $$\ge$$ ≥ 99%, F1 score $$=$$ = 100%), and turning (IC: recall $$\ge$$ ≥ 85%, precision $$\ge$$ ≥ 95%, F1 score $$\ge$$ ≥ 91%; FC: recall $$\ge$$ ≥ 84%, precision $$\ge$$ ≥ 95%, F1 score $$\ge$$ ≥ 89%). Conclusions Shank-mounted IMUs can be used to detect gait events during straight-line walking, slalom walking and turning. However, more false events were observed during turning and more events were missed during turning. For use in daily life we recommend identifying turning before extracting temporal gait parameters from identified gait events.

Effects of music-based movement therapy on motor function, balance, gait, mental health, and quality of life for patients with Parkinson’s disease: A systematic review and meta-analysis

2021 ◽  
pp. 026921552199052
Author(s):  
Zonglei Zhou ◽  
Ruzhen Zhou ◽  
Wen Wei ◽  
Rongsheng Luan ◽  
Kunpeng Li
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Function ◽  
Meta Analysis ◽  
Freezing Of Gait ◽  
Movement Therapy ◽  
Walking Velocity

Objective: To conduct a systematic review evaluating the effects of music-based movement therapy on motor function, balance, gait, mental health, and quality of life among individuals with Parkinson’s disease. Data sources: A systematic search of PubMed, Embase, Cochrane Library, Web of Science, PsycINFO, CINAHL, and Physiotherapy Evidence Database was carried out to identify eligible papers published up to December 10, 2020. Review methods: Literature selection, data extraction, and methodological quality assessment were independently performed by two investigators. Publication bias was determined by funnel plot and Egger’s regression test. “Trim and fill” analysis was performed to adjust any potential publication bias. Results: Seventeen studies involving 598 participants were included in this meta-analysis. Music-based movement therapy significantly improved motor function (Unified Parkinson’s Disease Rating Scale motor subscale, MD = −5.44, P = 0.002; Timed Up and Go Test, MD = −1.02, P = 0.001), balance (Berg Balance Scale, MD = 2.02, P < 0.001; Mini-Balance Evaluation Systems Test, MD = 2.95, P = 0.001), freezing of gait (MD = −2.35, P = 0.039), walking velocity (MD = 0.18, P < 0.001), and mental health (SMD = −0.38, P = 0.003). However, no significant effects were observed on gait cadence, stride length, and quality of life. Conclusion: The findings of this study show that music-based movement therapy is an effective treatment approach for improving motor function, balance, freezing of gait, walking velocity, and mental health for patients with Parkinson’s disease.

scholarly journals Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson’s Disease

Metabolites ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 14
Author(s):  
Petr G. Lokhov ◽  
Dmitry L. Maslov ◽  
Steven Lichtenberg ◽  
Oxana P. Trifonova ◽  
Elena E. Balashova
Keyword(s):  
Parkinson’S Disease ◽  
Molecular Weight ◽  
Parkinson's Disease ◽  
High Resolution Mass Spectrometry ◽  
Early Stage ◽  
Disease Diagnosis ◽  
The Body ◽  
Low Molecular Weight ◽  
Low Molecular Weight Compounds

A laboratory-developed test (LDT) is a type of in vitro diagnostic test that is developed and used within a single laboratory. The holistic metabolomic LDT integrating the currently available data on human metabolic pathways, changes in the concentrations of low-molecular-weight compounds in the human blood during diseases and other conditions, and their prevalent location in the body was developed. That is, the LDT uses all of the accumulated metabolic data relevant for disease diagnosis and high-resolution mass spectrometry with data processing by in-house software. In this study, the LDT was applied to diagnose early-stage Parkinson’s disease (PD), which currently lacks available laboratory tests. The use of the LDT for blood plasma samples confirmed its ability for such diagnostics with 73% accuracy. The diagnosis was based on relevant data, such as the detection of overrepresented metabolite sets associated with PD and other neurodegenerative diseases. Additionally, the ability of the LDT to detect normal composition of low-molecular-weight compounds in blood was demonstrated, thus providing a definition of healthy at the molecular level. This LDT approach as a screening tool can be used for the further widespread testing for other diseases, since ‘omics’ tests, to which the metabolomic LDT belongs, cover a variety of them.

scholarly journals Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson’s Disease

2021 ◽  
Vol 22 (12) ◽  
pp. 6277
Author(s):  
Joanna A. Motyl ◽  
Joanna B. Strosznajder ◽  
Agnieszka Wencel ◽  
Robert P. Strosznajder
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cell Fate ◽  
Neuronal Death ◽  
Neurological Diseases ◽  
Alpha Synuclein ◽  
Lipid Mediator ◽  
Cell Defense ◽  
Promising Therapeutic Approach ◽  
S1p Receptor

Molecular studies have provided increasing evidence that Parkinson’s disease (PD) is a protein conformational disease, where the spread of alpha-synuclein (ASN) pathology along the neuraxis correlates with clinical disease outcome. Pathogenic forms of ASN evoke oxidative stress (OS), neuroinflammation, and protein alterations in neighboring cells, thereby intensifying ASN toxicity, neurodegeneration, and neuronal death. A number of evidence suggest that homeostasis between bioactive sphingolipids with opposing function—e.g., sphingosine-1-phosphate (S1P) and ceramide—is essential in pro-survival signaling and cell defense against OS. In contrast, imbalance of the “sphingolipid biostat” favoring pro-oxidative/pro-apoptotic ceramide-mediated changes have been indicated in PD and other neurodegenerative disorders. Therefore, we focused on the role of sphingolipid alterations in ASN burden, as well as in a vast range of its neurotoxic effects. Sphingolipid homeostasis is principally directed by sphingosine kinases (SphKs), which synthesize S1P—a potent lipid mediator regulating cell fate and inflammatory response—making SphK/S1P signaling an essential pharmacological target. A growing number of studies have shown that S1P receptor modulators, and agonists are promising protectants in several neurological diseases. This review demonstrates the relationship between ASN toxicity and alteration of SphK-dependent S1P signaling in OS, neuroinflammation, and neuronal death. Moreover, we discuss the S1P receptor-mediated pathways as a novel promising therapeutic approach in PD.

Sign in / Sign up

Export Citation Format

Share Document